Trial Profile
Safety, tolerability and pharmacokinetics of ruxolitinib in healthy Japanese volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 12 Jan 2015
Price :
$35
*
At a glance
- Drugs Ruxolitinib (Primary)
- Indications Breast cancer; Chronic lymphocytic leukaemia; Colorectal cancer; Essential thrombocythaemia; Haematological malignancies; Hodgkin's disease; Myelofibrosis; Non-small cell lung cancer; Pancreatic cancer; Polycythaemia vera; Thalassaemia
- Focus Adverse reactions; Pharmacokinetics
- 12 Jan 2015 New trial record